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Analysis of murine leukemia virus (MuLV)l-induced leukemogenesis has dem- 
onstrated a  strong correlation between in vivo expression of virus with recom- 
binant env genes and disease (for a  review, see reference 1).  In mouse strains 
with  a  high  incidence of spontaneous  thymic  lymphoma,  such  as  AKR,  the 
generation of env  gene recombinants is an age-dependent, preleukemic event 
(2-4)  apparently resulting  from  recombination between replicating ecotropic 
virus and endogenous xenotropic virus-related sequences (4-10).  Such recom- 
binant viruses, also termed mink cell focus-inducing (MCF) viruses (3), appear to 
play a direct role in the disease process. Leukemia development can be acceler- 
ated by the injection of neonatal or young adult AKR mice with cloned isolates 
of MCF virus (11-13). MCF viruses are thymotropic (12-15)and rapidly establish 
infection of thymocytes, resulting in the expression of high levels of MCF virus- 
coded gp70  on  the cell surface (13,  14).  Thus,  infection by newly generated 
MCF viruses accounts for amplified expression of MuLV gp70 on thymocytes, 
one of the critical changes observed in the late preleukemic period (5-7 mo of 
age) of spontaneous  leukemogenesis in  AKR  mice (2,  16).  A  second  change 
ascribed to the late preleukemic period in  AKR mice is a  shift in quantitative 
expression of Thy-1 and H-2 alloantigens on thymocytes from high Thy-1/low 
H-2 to low Thy-1/high H-2 (16,  17). These findings have been interpreted as a 
shift to a more mature thymocyte phenotype during leukemogenesis. However, 
the thymus is an organ in which a complex and incompletely understood program 
of T  cell differentiation is  occurring.  The  thymus includes a  number of cell 
populations that express Thy-1 and H-2 as well as other T  lymphocyte markers 
such as Lyt-1 and Lyt-2 in varying amounts (for a  review, see  18).  Analysis of 
AKR leukemogenesis properly should take changes in these subpopulations into 
account. 
In this report we describe a sequential series of cellular changes in thymus of 
AKR mice during development of MCF virus-accelerated leukemia. This study 
differs in certain critical respects from previous studies of spontaneous leukemia 
in this strain.  First,  in spontaneous leukemogenesis there is considerable asyn- 
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chrony  in  the  kinetics  of appearance  of MCF  viruses and  initiation  of disease 
development, which may account for the extended range of latent period in this 
system  (12,  13).  It  is  also  unclear  to  what  extent  independent  recombination 
events in  individual  AKR mice  generate  MCF viruses that  differ in  biological 
activity. Thus,  one  cannot  assume that  all  AKR mice of a  certain  age will  be 
infected by the same MCF virus or will be at the same stage of leukemogenesis. 
We  have  attempted  to  overcome  such  uncertainties  by studying  MCF  virus- 
accelerated disease in young mice where leukemia development was rapid and 
synchronous after  intrathymic  injection  of cloned MCF virus isolates.  Second, 
we used the flow cytometric technique of correlated dual parameter analysis of 
forward angle light scatter and fluorescence to measure changes in cell size and 
in  the  expression  of differentiation  alloantigens  or  viral  gp70  on  specifically 
resolved thymocyte subpopulations.  Previous studies of spontaneous AKR leu- 
kemia  used  cytotoxicity assays  (16,  17)  or  single  parameter  flow  cytometric 
analysis of immunofluorescence (21) to measure changes in antigen  expression 
in the bulk thymocyte population but could not discriminate age-dependent from 
virus-induced changes nor relate such changes to specific thymocyte subpopula- 
tions. 
Three stages of leukemogenesis were defined before the appearance of frankly 
leukemic mice. Stage I represented steady-state infection of thymocytes by MCF 
virus without apparent  changes in light scatter properties of the cells or in the 
expression  of several differentiation  alloantigens  on the  major thymocyte sub- 
populations. Stage II was observed as early as 42 d postinjection and represented 
the  emergence  of a  clonal  population  of cells  with  restricted  transplantation 
properties.  These  cells  could  be  resolved  from  normal  thymocytes  by  flow 
cytometry.  Stage  III  was observed when  considerable  enlargement  of thymus 
had  occurred  and  represented  the  outgrowth  of fully  transformed  cells  that 
replaced the normal thymocyte subpopulations.  Our results are consistent with 
MCF virus transformation  of immature  thymocytes, i.e.,  cells in the lineage to 
the  small  cortisone-sensitive  thymocyte subpopulation  which  normally  express 
Thy-1, Lyt-1, Lyt-2, L3T4a, and H-2K antigens, receptors for peanut agglutinin, 
and an antigen recognized by monocional antibody B2A2 (22). 
Materials and Methods 
Virus Inoculation.  Female AKR/J mice (40-45 d old) were anaesthetized  by intraper- 
itoneal  injection  of avertine (aqueous solution of 290 mg 2,2,2-tribromoethanol-160 mg 
isoamyl alcohol  per kilogram  body weight).  The thymus was then exposed surgically as 
described by Kaplan (23) and the left lobe injected with 0.05 ml of MCF 69L1 virus (13) 
or tissue culture medium as control. Virus inocula contained ~5 ×  10 4 infectious units as 
determined by immunofluorescent focus assay on mink cells (13). 
Antibodies  and Fluorescent  Reagents.  Monoclonal  mouse IgG2a antibody (19-E12) to 
Thy-l.1  (24) was provided by Dr.  R. Nowinski,  Genetic Systems, Seattle.  Monoclonal 
mouse IgG2b antibody (2-2.1) to Lyt-l.2, mouse IgG2 antibody (116-13.1)  to Lyt-2.1, 
and mouse IgG2a antibody (TL.m4) to TL.2 were provided by Dr. F.-W. Shen and Dr. 
E. A. Boyse of this institution  (25, 26). Monoclonal  mouse IgM antibody (6]68) to Thy- 
1.2, mouse IgG2 antibody (100-5-R 18) to H-2K  k, and mouse IgG2a antibody (17/227) to 
I-A  k were provided by Dr.  U. Hammerling of this institution  (27,  28).  Monoclonal  rat 
IgG2b antibody (GK-I.5)  to  L3T4a  (29) was provided by Dr.  F.  Fitch,  University of 
Chicago. Monoclonal rat IgG2a antibody (35/56) to the gp70  f epitope has been described 916  STAGES  IN  DEVELOPMENT  OF  LEUKEMIA  IN  AKR  MICE 
previously (14, 30). Monoclonal mouse IgM antibody (514), which recognizes MCF virus 
gp70  specifically (31),  was  provided  by  Dr.  M.  Cloyd,  National  Institutes  of Health. 
Monoclonal rat antibody B2A2, which recognizes predominantly small cortical thymocytes 
(22), was provided by Dr. P. Bartlett and Dr. R. Scollay, Walter and Eliza Hall Institute, 
Melbourne, Australia. Antibodies present in sera of hybridoma-bearing nude mice (Thy- 
1.1, 35/56), ascites fluids of hybridoma-bearing mice (Thy-l.2, Lyt-l.2, Lyt-2.1, H-2K, I- 
A, TL.m4), or concentrated hybridoma culture fluids (514, B2A2) were diluted in medium 
and used at saturating concentrations. 
Fluorescein  isothiocyanate-conjugated anti-mouse and anti-rat  immunoglobulin sera 
were obtained from the Viral Oncology Program, National Cancer Institute. Fluorescein- 
ated peanut agglutinin (PNA) was obtained from Vector Laboratories, Inc., Burlingame, 
CA and used at a dilution of 1:800. 
Immunofluorescence  Assays.  Thymus or thymoma tissue was dispersed in a No. 22 tissue 
grinder (Kontes Co., Vineland, N  J) in the presence of Dulbecco's modified Eagle's medium 
(DME) containing  10%  fetal calf serum (FCS).  Cell clumps were removed by pipetting 
through Nitex nylon cloth (Tetko Inc., Elmsford, NY). In some instances, especially for 
thymomas, the cell suspension was centrifuged for 10 min at 1,000 g on a  3 ml cushion 
of lymphocyte separation medium (Litton Bionetics,  Inc., Kensington,  MD) to remove 
nonviable cells and erythrocytes. Viability of thymocytes prepared in this way was consist- 
ently  >90%.  Cells  were  added  to  3-ml  conical  centrifuge  tubes  (Bellco  Glass,  Inc., 
Vineland, N  J) (3 x  106 cells per reaction) which were prewet with DME containing 5% 
FCS and 0.1%  sodium azide and centrifuged at  1,000 g for 10  min at 4°C.  Cells were 
resuspended in 0.3 ml of medium containing primary antibody at the appropriate dilution 
for saturating conditions and incubated on ice for 30 min with periodic shaking. After 
incubation, the cell suspension was centrifuged as above through a 0.5 ml FCS cushion, 
resuspended in 0.3 ml of medium containing a 1:25 dilution of appropriate fluoresceinated 
antiimmunoglobulin, and incubated on ice for 30 min. To control for nonspecific fluo- 
rescence, cells also were incubated with  normal mouse serum or normal rat serum as 
appropriate, followed by incubation with the specific fluoresceinated antiimmunoglobulin 
reagent. After a final centrifugation of the cells through a 0.5 ml FCS cushion,  1 ml of 
medium was added per tube. Before analysis by flow cytometry, the cells were resuspended 
and pipetted through Nitex nylon cloth to remove clumps. 
Flow Cytometric Analysis.  A multiparameter cell sorter (EPICS V; Coulter Electronics 
Inc.,  Hialeah,  FL)  was used  to analyze forward  or  low angle  light  scatter and  green 
fluorescence from fluorescein isothiocyanate-conjugated antibodies bound per cell. Green 
fluorescent light excited by an argon laser (164-05; Spectra-Physics, Inc., Mountain View, 
CA) tuned to 488 nm was collected using 515-nm long-pass and 530-nm short-pass filters. 
For single parameter analysis, light scatter or fluorescence intensity was divided into 256 
channels; for dual parameter analysis, the division was 64 channels. Fluorescence intensity 
was determined  by both  a  three  decade  logarithmic amplifier and a  linear amplifier. 
Linear amplification is useful in analyzing the fluorescence of cell populations that show 
broad or skewed distribution patterns such as Lyt-1 or gp70, while logarithmic amplifi- 
cation  provides a  powerful  means of resolving discrete  populations of cells that differ 
markedly in  fluorescence  intensity,  especially positive and  negative populations.  Daily 
calibration was performed using both 10-#m fluorescent microspheres (Coulter Electron- 
ics, Inc.) and immunofluorescent staining of control thymocytes with anti-Thy-1 antibody. 
For linear amplification, the major peak fluorescence intensity of Thy-1 was set at channel 
100 at a  gain of 2.  Fluorescence reactions of all other antibodies were then  measured 
relative to Thy-1 : Lyt-l.2, gain of 20; Lyt-2.1, gain of 5; L3T4a, gain of 20; B2A2, gain 
of 20; H-2K  k, gain of 20; gp70, gain of 20. For light scatter analysis, the peak scatter of 
the predominant thymocyte subpopulation was set at channel  100 by adjusting the laser 
power. Under these conditions, dead cells and erythrocytes that scatter light less intensely 
are  scored in  channels  <80  (32)  and  were excluded  from analysis of fluorescence by 
appropriate gating techniques (33). The results of the analysis of 10,000 viable cells are 
presented as 64 × 64 channel isocontour displays of fluorescence intensity per cell (y axis) 
as a function of forward angle light scatter (x axis). The contour intervals, shown by three O'DONNELL,  WOLLER,  AND  CHU  917 
intensities of shading, were chosen arbitrarily to indicate the peak areas of the correspond- 
ing three-dimensional  histograms.  Depending  on antibody  used,  the  contour  intervals 
represent 2,  10, and 20-80  cells per channel. As a result of such data reduction, it was 
then possible using available  software to integrate different areas of a contour plot and to 
determine the percent of total cells per area as well as to determine modal fluorescence 
and light scatter coordinates. 
Transplantation Bioassay.  Since AKR/J and AKR/Cu mice express different alleles of 
Thy-1 antigen on thymocytes, an assay for transformed phenotype of MCF virus-infected 
AKR/J thymocytes was performed by transplanting 5 ×  108 cells intravenously or intra- 
peritoneally  into  2-4-mo-old  AKR/Cu  recipients.  Resultant  leukemias  were  typed  as 
donor AKR/J or recipient AKR/Cu by membrane immunofluorescence assays of Thy-1.1 
or Thy-l.2, respectively (34). The incidence of spontaneous leukemia in a population of 
112  AKR/Cu  mice was determined  as a  control  for these  studies.  The  median  latent 
period of leukemia development (303 d of age) was significantly longer than that observed 
for AKR/J mice (232 d of age).  In some experiments, virus-infected AKR/J thymocytes 
were transplanted  into AKR]J  mice  by  intravenous,  intraperitoneal,  or  intramuscular 
routes. In these instances, donor and recipient leukemias could not be established  un- 
equivocally but successful transplantation  was assumed if multicentric leukemia resulted 
in a latent period of -30  d or less or if a large tumor mass grew in thigh muscle at the 
site of injection. 
Results 
Kinetics of Virus-accelerated Leukemia.  Fig. 1 shows that leukemia development 
occurs rather synchronously in a population of AKR mice injected intrathymically 
with a cloned isolate of MCF virus, in contrast to that observed for spontaneous 
development  of leukemia  in  this  strain  of mice.  After  injection  of MCF  69L1 
virus,  mice  showing  signs  of frank  leukemia  (ruffled  fur,  hunched  appearance 
with  chest  enlargement,  labored  breathing,  lymph  node  enlargement)  were 
observed  until  ~60  d  postinjection.  Incidence  of disease  then  rose  sharply  to 
>90%  within  100 d  postinjection  (median  latent period,  76 d). Thus, a study of 
the  time course  of changes  in thymus  of virus-injected  mice during the preleu- 
kemic period can be considered a feasible undertaking. 
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FIGURE  1.  Development of virus-accelerated leukemia in AKR/J mice. Cumulative incidence 
of frank thymic lymphoma in female AKR/J mice injected intrathymically at 40-45 d of age 
(arrow) with 5  X  10" infectious units of MCF 69L1  virus (O) or with tissue culture medium as 
control (- -  -).  Incidence  of spontaneous  leukemia  in control and unmanipulated  mice  was 
identical (13). 918  STAGES IN  DEVELOPMENT OF  LEUKEMIA IN  AKR MICE 
Stages in  Development of Virus-accelerated Leukemia.  Thymocyte subpopula- 
tions were characterized by established surface markers at different time intervals 
from the time of virus injection to the appearance  of frankly leukemic mice. 
Immunofluorescence reactions  of thymocytes with  monoclonal antibodies  di- 
rected against differentiation alloantigens (Thy-1, Lyt-1,  Lyt-2,  L3T4a,  B2A2, 
H-2K),  viral  gp70,  or  with  fluoresceinated  PNA  were  quantitated  by  flow 
microfluorometry.  Correlated  two-parameter  analysis  of forward  angle  light 
scatter and fluorescence intensity was determined for each surface marker (Figs. 
2-5). 
Control  Mice.  The  identity  of thymocyte  subpopulations  defined  by  flow 
cytometric analysis has been well-described (reviewed in  18).  Briefly, four sub- 
populations were resolved by Thy-1  staining (Fig. 2).  Population  1, with inter- 
mediate Thy-1 fluorescence and modal scatter of 25, represents small, cortisone- 
sensitive, cortical thymocytes; population 2, with the lowest Thy-1  fluorescence 
and modal scatter of 28, represents small, cortisone-resistant, medullary thymo- 
cytes which are also immunocompetent; population 3, with high Thy-1  fluores- 
cence and light scatter of 32-44, represents medium-sized thymic lymphoblasts; 
population 4  is a  mixture  (~12:1),  consisting of population  1 doublets and  a 
second population of cells with the highest Thy-1 fluorescence and light scatter 
of 40-59,  which  represents  large  thymic  lymphoblasts.  The  composition  of 
population 4 was determined by sorting cells onto slides and quantitating doublets 
and large cells. Doublet formation is an artifact of the indirect immunofluores- 
cence procedure used in these studies, which results from cross-linking of antigens 
present in very high density, like Thy-1. Thymic lymphoblasts were characterized 
as  cycling cells  by  acridine  orange  staining  and  by  Thy-1  fluorescence  after 
separation from total thymocytes by centrifugal elutriation (F. Traganos and P. 
O'Donnell, unpublished results). 
Fig. 2 also shows the expected patterns of expression of Lyt-1, Lyt-2, and H- 
2K antigens on control cells, based on published data (18).  Lyt-1  fluorescence 
varied  from  predominantly  dull  to  very  bright.  Because  of the  light  scatter 
overlap of small cortical and medullary cells, it was difficult to resolve the staining 
patterns of individual populations. However, analysis of cortisone-resistant cells 
(data not shown) revealed that the fluorescence intensity of medullary cells was 
much higher than that of cortisone-sensitive cortical cells as reported by Scollay 
and Shortman (18). Thus, the phenotype of small cortical thymocytes was Lyt-1 
low, Lyt-2 high, and H-2K low. Medullary cells were Lyt-1 high, H-2K high but 
were also  resolved  into  two populations of Lyt-2-  and  Lyt-2 + cells that  were 
present  in a  ratio  of ~2:1,  respectively.  The fluorescence intensity of thymic 
lymphoblasts (light scatter, >32) appeared to be relatively low for Lyt-1 and H- 
2K and high for Lyt-2. 
Fig. 3, panel 1 shows the pattern of expression of L3T4a antigen on control 
AKR thymocytes. L3T4a was defined recently by monoclonal antibody GK-1.5 
and appears  to be an antigenic determinant of the murine homologue of the 
human Leu 3/T4 molecule on T  cells that is involved in class II major histocom- 
patibility complex reactivity (29,  35).  Small cortical thymocytes express a  high 
level of L3T4a while medullary thymocytes are divided into L3T4a + and L3T4a- 
subpopulations (35). O'DONNELL,  WOLLER,  AND  CHU  919 
FIGURE 2.  Fluorescence distribution patterns ofpreleukemic AKR/J thymocytes stained with 
monoclonal antibodies to differentiation alloantigens or to  MuLV gp70.  Mice (40-45  d  of 
age) were injected intrathymically with MCF 69L1  virus or tissue culture medium as control. 
Mice were thymectomized at different time intervals postinjection and assayed for expression 
of alloantigens Thy-1, Lyt-l, Lyt-2, H-2K, or MuLV gp70 by immunofluorescence assay  of 
viable  cells.  Membrane  fluorescence  was  quantitated  by  flow  cytometry  as  described  in 
Materials and Methods: Thy-1, linear amplification at a gain of 2; Lyt-1, linear amplification 
at a gain of 20; Lyt-2, logarithmic amplification; H-2K, logarithmic amplification; gp70, linear 
amplification at a  gain of 20.  Thymus weights of individual mice: control,  122 mg; stage I, 
120  rag;  stage  II  (a)  124  mg,  (b)  189  mg; stage  llI (a)  309  rag,  (b)  397  rag.  Four  major 
subpopulations of thymocytes were resolved by Thy-1 staining as indicated in the contour map 
of control mice. Arrows indicate the modal light scatter of the novel cell population observed 
at stage II. 
Stage L  We have shown previously that  steady-state infection of AKR thy- 
mocytes is reached by 28 d after injection of ~5  x  104 infectious units of MCF 
69L 1 virus (13, 14). At this time postinjection, >60% of thymocytes  were infected 
by MCF virus and expressed levels of MuLV gp70 on their cell surface above 920  STAGES  IN  DEVELOPMENT  OF  LEUKEMIA  IN  AKR  MICE 
FIGURE  3.  Fluorescence distribution patterns of preleukemic and leukemic AKR/J thymo- 
cytes stained with monoclonal antibody to L3T4a antigen. Control thymocytes (panel 1) or 
thymocytes of MCF 69Ll-injected mice at stage I (panel 2), stage II (panel 3), and stage III 
(panel 4) of leukemogenesis were analyzed at 69 d  postinjection. Staging was confirmed by 
parallel analysis of Thy-1, B2A2, and gp70 expression (data not shown). Primary leukemias 
were analyzed at 106 d (panel 5) and 103 d (panel 6) postinjection. Logarithmic amplification 
of fluorescence intensity was used. The pattern of L3T4a expression in panel 6 in which 50% 
of the cells were L3T4a- was observed in 1/9 leukemias examined. 
those of control  mice  injected  with  tissue  culture  medium  (Fig.  2).  Increased 
gp70 expression is encoded specifically by MCF virus and not other endogenous 
MuLV (14). This observation was confirmed in the present studies by use of an 
MCF-specific gp70 monoclonal antibody 514 (31) which gave results identical to 
those shown in Fig. 2 with antibody to the gp70  f epitope. It can be seen that the 
gp70 fluorescence intensity is skewed from dull  to very bright,  possibly a  gene 
dosage effect of the infection of thymocytes in the population at varying multi- 
plicities.  Also,  at  this  stage  of leukemogenesis,  the  frequency  of thymocytes 
producing  MCF  viruses as  measured  by infectious center assay on  S+L  -  mink 
cells is maximum  (0.1-0.3%)  and constant  for the duration  of the preleukemic 
period. The expression of high levels of MCF viral gene products intracellularly 
and on the cell surface but low levels of mature,  infectious virus is characteristic 
of virus-infected thymocytes and leukemia cells (14, 36). 
We  attempted  to  determine  the  relative  contribution  of small  cortical  and 
medullary  thymocytes  to  the  observed  gp70  fluorescence  and  to  MCF  and 
ecotropic virus infectious centers measured in total thymocyte suspensions. Mice 
injected with MCF 69L 1 virus were administered cortisone at 42 d postinjection 
and analyzed for gp70 expression or infectious centers 72 h  later.  As shown in 
Table  I,  cortisone-resistant  (medullary)  thymocytes express  low levels of MCF O'DONNELL,  WOLLER,  AND  CHU  921 
FIGURE 4.  FluorescencedistributionpatternsofpreleukemicAKR/Jthymocytesstainedwith 
Thy-1 or B2A2 monoclonal antibodies or with fluoresceinated PNA. Thymocytes of MCF 
69L1-injected mice were analyzed at 69 d postinjection. Cells were characterized as stage I, 
II, or III on the basis of Thy-1 staining as shown in Fig. 2 and of gpT0 staining (data not 
shown). Thymus  weights: stage  I,  80  rag; stage II,  225  rag, stage Ill,  411  mg.  Linear 
amplification: Thy-I at gain of 2, B2A2 at gain of 20. Logarithmic amplification: PNA. By 
logarithmic amplification the fluorescence intensity of medullary thymocytes compared with 
normal rat serum controls was identical for B2A2 but significantly  higher for PNA. 
virus as judged by a  threefold decrease in  fluorescence intensity almost to the 
level  of endogenous  MuLV  gp70  expression  observed  for  controls.  Also,  we 
observed a  marked reduction  (up to  200-fold)  in  the frequency of MCF  69L1 
infectious centers.  The  infectious centers  observed  in  cortisone-resistant  cells 
may be due,  in  fact,  to residual  contaminating cortical thymocytes because,  in 
separate  experiments,  we  observed  that  at  least  80%  of total  MCF  infectious 
centers were recovered in the major cortical thymocyte subpopulation  that was 
sorted on  the basis  of Thy-1  fluorescence (cf.,  Fig.  2).  This result with  sorted 
cells  also  indicated  that  the  low  frequency  of  MCF  69L1  infectious  centers 
observed in the bulk thymocyte population was characteristic of lymphoid cells 
and not a  minority cell population in the thymus such as stromal cells. 
As  shown  in  Figs.  2  and  3,  no differences were  detected  in  the  patterns  of 
expression of alloantigens between control and MCF virus-infected thymocytes 
at  stage  I  of leukemogenesis.  Fig.  4  shows  the  pattern  of expression  of PNA 
receptors on thymocytes at stage  I,  which  was identical to that of control mice 
(data not shown).  As described previously by others (18,  37,  38),  small cortical 
thymocytes and thymic lymphoblasts express high levels of receptor while med- 
ullary cells express  low  but significant  levels.  The  relative  frequency of virus- 
injected mice whose thymocytes displayed stage  I  phenotype was  maximum  at 
40 d  and declined thereafter (Fig. 6). 
Stage  II.  As  early  as  42  d  after  injection  of  MCF  69L1  virus,  occurring 922  STAGES IN  DEVELOPMENT  OF  LEUKEMIA IN  AKR  MICE 
FIGURE 5.  Fluorescence distribution patterns of MCF 69L1 virus-accelerated AKR/J leu- 
kemias stained with monoclonal antibodies to differentiation alloantigens or to MuLV gp70. 
Primary AKR/J thymomas M75, M97, M81 were observed at 77 d postinjection of MCF 69L 1 
virus and analyzed as described in Fig. 2 legend and in Materials and Methods. Thymoma 
weights: M75, 1128 mg; M97, 692 mg; M81,650 rag. M81-T1 was a primary transplant to 
an AKR/Cu recipient and was derived from a metastatic deposit in the mesenteric lymph node 
at 21 d after intraperitoneal inoculation. 
maximally at 50-60 d  postinjection (Fig. 6), a novel population of cells could be 
identified in the presence of normal thymocyte subpopulations on the basis of its 
characteristic light scatter and its unique pattern of staining with antibodies  to 
alloantigens and MuLV gp70. Representative examples are shown in Figs. 2 and 
3.  As indicated by the arrows, the new cell population was distinguished by (a) 
light scatter that was  higher than  that of the predominant  population of small 
cortical thymocytes, (b) high gp70  fluorescence, (c) Thy-1  fluorescence compa- 
rable to or slightly less than that of cortical thymocytes, and (d) H-2K fluorescence 
that was intermediate between cortical and medullary thymocytes. Lyt-1, Lyt-2, 
and  LBT4a fluorescence was  comparable to  that  of small  cortical thymocytes. 
Fig.  4  shows that the PNA fluorescence of stage II cells also was comparable to 
that of small cortical thymocytes. 
In  Fig.  2,  the thymus weight of one of the stage  II mice was comparable  to 
that of controls while the other was slightly enlarged. It is clear that the percent 
of the stage II cell population is increased in the mouse with the enlarged thymus 
but in neither case is the population well-resolved from other subpopulations by 
the  monoclonal  antibodies  used.  More  recently,  we  obtained  a  monoclonal 
antibody B2A2 isolated by Bartlett et al. (22) which recognizes antigen present O'DONNELL, WOLLER,-AND CHU  923 
TABLE  I 
Effect of Cortisone Treatment on Expression of gp 70 and Mature Infectious Ecotropic Virus or 
MCF Virus by AKR/J Thymocytes 
Injection 
MuLV gp70*  Infectious centers* per 106  Percent 
cells  residual 
Percent  cortical 
MFLR  ECO  MCF 69L1  thymocytes  e  positive 
Control + saline 
Control + cortisone 
69L1 + saline 
69L1 + cortisone 
47  15  1,187  <0.02 
52  14  437  <0.02 
40  14  232  <0.02 
36  13  1,050  <0.02 
82  79  800  1,025 
79  108 
78  102 
80  103 
80  115 
53  21  345  15 
55  23  800  5 
54  39 
59  40 
42  19 
61  25 
62  52 
7 
11 
13 
5 
<5 
12 
<5 
12 
13 
Mice injected  intrathymically  with  MCF  69L1  virus  or tissue  culture  medium  (control)  were 
administered cortisone acetate (125  mg per kg body weight) or saline intraperitoneally  at 42 d 
postinjection.  Such cortisone treatment resulted  in a maximum flvefold decrease in thymus weight 
within 72 h, the time chosen for immunofluorescence assay and infectious center assay of virus- 
infected thymocytes. 
* Immunofluorescent assay of gp70  f epitope  expression.  Data are given  as  median fluorescence 
intensity (MFLR) of cells with fluorescence  greater than normal rat serum controls determined by 
subtraction of single-parameter  fluorescence  histograms (fluorescence intensity range, 0-255). 
* Ecotropic MuLV infectious  centers are given as XC plaque-forming units.  MCF 69L1 infectious 
centers are given as S+L  - mink focus-forming units. 
0 Residual cortical thymocytes not lysed by cortisone treatment were quantitated by integrating the 
appropriate area of the two-parameter Thy-I contour map. 
almost exclusively  on  the  small  cortical  thymocyte subpopulation.  Fig.  4  shows 
the  characteristic  staining  pattern  of  B2A2  antibody  compared  with  Thy-1 
antibody  for  virus-infected  stage  I  thymocytes.  This  pattern  was  identical  to 
control thymocytes (data not shown). Cortical thymocytes stained positively while 
medullary  thymocytes were  negative  or very low.  Fig.  4  also shows that  B2A2 
staining of thymocytes resolved  the novel stage  II cell population  from cortical 
thymocytes unambiguously.  The  modal  light scatter  of this new cell population 
was 30 compared with  25 for cortical  thymocytes and  28 for medullary thymo- 
cytes.  Stage  II cells  represented  41%  of the  total  thymocyte population  in  this 
particular mouse. 
It appears that the novel population of cells observed at what we have defined 
as stage  II has a  distinct  phenotype  because  43  virus-injected  mice  showed the 
same characteristic  patterns  of forward  light  scatter and  fluorescent  staining as 
shown in Figs.  2-4.  Stage  II also was observed in AKR mice injected  with MCF 
247  and  MCF  13  viruses  and in  C3Hf/Bi  mice injected  with  AKR  SL3-2 virus 
(39),  indicating  that  this  is  not  a  phenotype  unique  to  MCF  69L1  virus  or  to 924  STAGES  IN  DEVELOPMENT  OF  LEUKEMIA  IN  AKR  MICE 
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FIGURE  6.  Relative frequency of stages of leukemogenesis as a function of time after injection 
of MCF virus. AKR/J mice (40-45 d old) were injected intrathymically with MCF 69L1  virus. 
Mice were sacrificed at appropriate intervals of time postinjection and characterized as stage 
I  (A),  II  (B),  or  III  (C)  of leukemogenesis during  the  preleukemic  period  or  as  primary 
leukemias (D) as described in the text. Data represents a  total sample of 137 mice (stage I, n 
=  51; stage II, n  =  33; stage III, n  =  18; primary leukemia, n  =  35). 
AKR mice. By integrating regions of the contour plots of different antigens that 
correspond to the new population of cells we estimated that stage II thymocytes 
represent  15-45%  of total cells depending on thymus weight. Stage II changes 
also were observed to occur asymmetrically within  a  single  thymus.  In  several 
mice each of whose thymus lobes were dissected and analyzed separately, there 
was evidence of stage I in one lobe and stage II in the other or stage II in one 
lobe and stage III in the other. The most advanced stage was observed invariably 
in the lobe that received the initial injection of virus. 
Stage III.  Figs.  2-4  show representative  dual parameter  analyses of thymo- 
cytes from  four virus-injected  mice  in  which  considerable  enlargement  of the 
thymus had occurred (thymus weight, >300 mg). Mice at this stage of leukemo- 
genesis  did  not  display  signs  of  frank  leukemia,  i.e.,  ruffled  fur,  hunched 
appearance with chest enlargement,  labored breathing,  or lymph node enlarge- 
ment. At stage III, normal thymocyte subpopulations were replaced by a  more 
homogeneous  population  defined  by light  scatter  and  fluorescence.  Stage  III 
cells showed increased light scatter compared with stage II cells. The light scatter 
of stage III cells from individual mice (n =  18) varied from 30 to 36 and in one 
mouse two cell populations  that  differed by light scatter were observed in  the O'DONNELL,  WOLLER,  AND  CHU  925 
same thymus (Fig. 2, llIb). In general, the fluorescence intensities of thymocyte 
makers Thy-1, Lyt-1, Lyt-2, L3T4a, B2A2, H-2K, and PNA observed for stage 
III cells were those predicted on the basis of outgrowth of cells with stage II 
phenotype. However, gp70 fluorescence was lower and more variable than that 
observed on stage II cells. The frequency of mice at stage III of leukemogenesis 
was maximum at 70 d postinjection (Fig. 6). Stage III cells appear, therefore, to 
represent outgrowth of transformed cells in thymus. 
Primary (Frank) Leukemias.  We analyzed 22  primary leukemias induced by 
MCF 69L1  virus and 5 primary leukemias induced by MCF  13 virus that were 
observed at 62-99  d  postinjection. The data confirmed an earlier report that 
the Lyt phenotype of spontaneous AKR leukemias is that of immature thymo- 
cytes, i.e.,  Lyt-l+2  + (21).  This conclusion was strengthened by the finding that 
primary leukemias were also L3T4a + (Fig.  3) and PNA  + (data not shown), two 
markers that are also found expressed at high levels on a subpopulation of thymic 
lymphoblasts and small cortical thymocytes (18, 29, 35). However, the resolving 
power of two-parameter flow  cytometry revealed considerable  heterogeneity 
among primary leukemias with respect to cell size and quantitative expression of 
antigens,  which has  not been reported previously.  Light scatter of individual 
leukemias varied from 28 to 44 with a median of 35. A striking observation was 
that two to three distinct populations of leukemia cells were present in 13 of 22 
leukemias induced by MCF 69L1 virus and in 1 of 5 leukemias induced by MCF 
13  virus.  Fig.  5  shows dual parameter analysis of three leukemias induced by 
MCF  69L1  virus  that  contained one,  two,  or  three  discrete  subpopulations, 
respectively. In the MCF  13  leukemia and in  10  of 13  MCF 69L1  leukemias, 
multiple tumor cell populations were distinguished by both light scatter and Lyt-2 
fluorescence intensity. Other alloantigens or gp70 also resolved distinct leukemic 
cell populations  as  illustrated by tumors  M97  and  M81  of Fig.  5  and by the 
tumor shown in Fig. 3, panel 6 but less frequently than did Lyt-2. The relative 
proportions  of leukemia cell  subpopulations  also  differed among the  tumors 
analyzed. Four leukemias containing multiple cell populations were transplanted 
into AKR/Cu mice and the resultant leukemias were subjected to dual parameter 
analysis to assay for the persistance of subpopulations. In each instance, multiple 
cell populations  were resolved among transplanted leukemia cells in the same 
relative proportions as in the inocula. Fig. 5  shows the analysis of one of these 
leukemias, M81,  containing three distinct subpopulations,  and the analysis of 
cells derived from the first transplant M8 l-T1. The two original cell populations 
with light scatter of 40 and 41 and characteristic staining patterns were resolved 
clearly in the transplanted leukemia. The third subpopulation comprising ~ 10% 
of cells in the primary leukemia did not transplant. It is possible that these cells 
may have represented residual normal thymocytes in the M81  tumor. 
It has been reported that MCF virus-infected thymocytes and leukemia cells 
express increased levels of Ia antigens compared with young AKR mice (40). 
Accordingly, we assayed preleukemic thymocytes or leukemia cells from a total 
of 39 injected AKR/J mice with monoclonal antibody to I-A  k but were unable 
to confirm these data.  Using logarithmic amplification, we observed that 43  ___ 
8% of control AKR thymocytes from medium-injected mice (3-4 mo old) showed 
Ia  fluorescence just  discernible above  the  background control.  This  level  of 926  STAGES IN  DEVELOPMENT OF  LEUKEMIA IN  AKR  MICE 
fluorescence was 60-100-fold lower than that of Thy-1. This same low fluores- 
cent staining with Ia antibody also was observed for virus-infected thymocytes at 
stages I, II, and III as well as for primary leukemia cells and we conclude that it 
is  not  highly  significant.  Similarly,  we  were  unable  to  detect  any  significant 
expression  of TL antigen  on  15  leukemias  using  monoclonal  antibody to  the 
TL.m4  epitope whose pattern  of reactivity conforms to TL.2  by conventional 
antisera (26). However, the reported frequency of anomalous TL expression on 
spontaneous AKR leukemias is ~11% (41), the limit of detection in our sample. 
Tissue Weights.  Changes in the masses of thymus, spleen, and liver correlated 
with the stage of leukemogenesis defined by flow cytometry. A sample of 65 age- 
matched  female  AKR/J  mice  were  injected  with  MCF  69L1  at  40  d  of age. 
Leukemogenesis was staged at weekly intervals as described above between 35 
and  123  d  of age.  There  was  no age-dependent  change  in  thymus  or  spleen 
weight  of control  mice  within  the  interval  studied  but  liver  weight  increased 
linearly with age (1,600-2,400 mg). Thymus of stage I mice (106 4- 22 mg, n -- 
25) showed a slight but significantly lower weight than medium-injected control 
mice (135 +  17, n =  8, P <  0.002). This difference was confirmed by comparing 
thymus weights from a much larger sample obtained by pooling data from several 
experiments.  In this instance thymus weight of stage I mice (101  4- 23 mg, n  = 
36) was significantly different from control mice (116 4- 26, n  =  22, P  <  0.05). 
Thus, an early consequence of virus infection is a depressive effect on the mass 
of thymus tissue. 
Stage II (168 _+ 69 mg), stage III (424 4-  168 mg), and leukemic (930 4- 365 
rag) thymuses showed a  progressive increase in mean thymus weight consistent 
with  emerging  tumor  growth  but  there  was considerable  variation  at  each  of 
these stages as indicated by the large standard deviations.  In the case of stage II 
mice, there was considerable overlap with stage I thymus weights, an observation 
demonstrating that it was possible to observe outgrowth of a  new population of 
thymocytes in the absence of gross changes in thymus weight. 
No significant  differences were observed between spleen  weights of control 
(81 4- 7 mg, n =  8), stage I (89 4- 13 rag, n -- 25), or stage II mice (91  4- 12 mg, 
n =  12).  However, spleen weights of 5 of 9 stage III mice and  10 of 11 leukemic 
mice exceeded 115 mg, the upper limit of normal spleen weight within the time 
interval  studied,  indicative  of metastatic  spread  of tumor  cells  to  this  tissue. 
Metastatic spread to the  liver indicated by a  tissue weight >2,400  mg was less 
pronounced  but  was observed in  4  of 9  stage  III  mice and  6  of 11  leukemic 
mice. 
Transformed  Phenotype  of  Thymocytes  at  Different  Stages of  Leukemogene- 
sis.  Transplantation  bioassays of cells at the various preleukemic stages defined 
by flow cytometric analysis or of primary leukemia cells were performed in AKR/ 
Cu mice or AKR/J mice as recipients (Table I1). AKR/Cu mice express the Thy- 
1.2 allele on thymocytes and thus allow donor AKR/J (Thy- 1.1) cells and recipient 
cells to be distinguished (34). Stage I cells from  11  donors were transplanted  to 
37  AKR/Cu  recipients.  Leukemias  with  a  mean  latent  period  of 110  d  were 
observed in 70% of recipients (over one leukemia per donor) but were Thy-l.2 
(recipient)  in  origin,  indicative  of MCF  virus  transfer  rather  than  transfer  of 
virus-infected AKR/J cells that were "committed" to transformation.  The latent O'DONNELL, WOLLER, AND CHU  927 
TABLE  II 
Transplantation Bioassay of MCF 69L l-infected AKR/J Thymocytes and Primary Leukemia 
Cells 
Recipient 
Donor  AKR/Cu*  AKR/J 
stage of 
leukemo-  No.  Percent  Latent  No.  Percent  Latent 
genesis  No.  recip-  leuke-  period  No.  recip-  leuke-  period  donors  donors  ients  mias  (days)  ients  mias  (days) 
I  11  37  70  110±  12  ND 
II  6  15  60  104 ±  9  8  20  85  24 ±  8 
Ill  2  4  100  23 ±  4  1  2  100  27 
°L  10  13  85  15 +  9  12  18  100  17 +  10 
In separate experiments, 5 x 106 cells were injected either intravenously or intraperitoneally into 
2-4-too-old AKR/Cu or AKR/J recipient mice. 
* Intrathymic injection of AKR/Cu mice (45-65-d-old) induced leukemia with a mean latent period 
of 87 d. 
period observed was consistent with a mean latent period of 87 d for MCF 69L1 
virus-accelerated leukemia in AKR/Cu  mice injected intrathymically at 40-65 
d of age. Similarly, stage II cells from six separate donors were transplanted into 
15 AKR/Cu recipients.  Leukemias were observed with a  mean latent period of 
104 d  in 60% of recipients (one or more leukemia per donor), also of recipient 
Thy-1 type. Thus, stage II cells failed to transplant but rather transferred virus 
passively to AKR/Cu mice.  In contrast,  stage III cells (two donors) or primary 
leukemia cells (8 of 10 donors) transplanted  in AKR/Cu mice with mean latent 
periods of 23  and  15  d,  respectively.  By transplantation  bioassay in  AKR/Cu 
mice, therefore,  it appeared that  transformed cells were first apparent at stage 
III.  However,  in  separate  experiments,  transplantation  to  AKR/J  recipients 
indicated that transformed cells could be detected as early as stage II of leuke- 
mogenesis.  Although  donor  and  recipient  could  not  be  distinguished  in  this 
instance, cells from 7 of 8 stage II donors injected intravenously or intraperito- 
neally  resulted  in  muhicentric  leukemias  with  a  mean  latent  period  of 24  d, 
indicative  of leukemic  cell  transfer.  This  conclusion  was strengthened  by the 
observation that cells of 3 of 7 of the same stage II donors also developed into a 
tumor in situ after intramuscular injection. Stage III cells and primary leukemic 
cells also transplanted  in AKR/J mice by all three routes of injection. 
It appears from the data of Table II that the limited transplantation phenotype 
of AKR/J stage  II  cells in  AKR/Cu  recipients  might  be Thy-1  related.  If this 
were true we would expect that in the reciprocal experiment, stage II cells from 
AKR/Cu  donors  would fail  to  transplant  into  AKR/J  recipients,  The  data  in 
Table  III  supports  this  hypothesis.  Transplantation  of stage  II  cells  from  six 
separate  AKR/Cu  donors  resulted  in  leukemia  development  in  39%  AKR/J 
recipients,  with a  mean  latent  period of 88 d.  These  leukemias were recipient 
Thy-1  type,  indicative  of the  passive transfer  of virus.  In  contrast,  leukemias 
were observed in  100% of AKR/Cu recipients injected with the same leukemia 
cells,  with a  mean  latent  period of 36  d.  In accord with  the data of Table  II, 928  STAGES  IN  DEVELOPMENT  OF  LEUKEMIA  IN  AKR  MICE 
TABLE  III 
Transplantation Bioassay of MCF 69L 1-infected AKR/Cu Thymocytes 
Recipient 
AKR/J  AKR/Cu  Donor  No. 
stage  donors 
No.  Percent  Latent period  No.  Percent  Latent 
recipients  leukemias  (days)  recipients  leukemias  period(days) 
II  6  18  39  88 +  6  18  100  36 +  6 
IlI  1  3  100  40  3  100  28 _+ 8 
In  the  same  experiment,  1-5  ×  106 cells  were  injected  intraperitoneally into  2-mo-old  AKR/J  or 
AKR/Cu  recipient mice. 
TABLE  IV 
Transplantation Bioassay of MCF 69L l-infected AKR/J Thymocytes and Primary Leukemia 
Cells in Irradiated and Unirradiated Recipients 
Recipients 
AKR/Cu  AKR/J 
Donor  No.  Irradiated*  Unirradiated  Unirradiated 
stage  donors 
Latent  No.  Percent 
recipients  leukemia  period 
(days) 
Latent  Latent  No.  Percent  No.  Percent  period  recipients  leukemia  (days)  recipients  leukemia  period 
(days) 
11  2  6  100  44+11  6  100  99:1=14  8  100  39=1::8 
°L  2  6  100  183=4  6  100  18-I-5  8  100  18:t:4 
In the same experiment, 1-5 x  l0  s cells were injected intraperitoneally into 43-49-d-old  AKR/Cu or AKR]J recipient mice. 
* 400 tad administered 1 h before injection. 
stage  III  cells  from  an  AKR/Cu  donor  transplanted  into  both  AKR/Cu  and 
AKR/J recipients, with mean latent periods of 28 and 40 d, respectively. 
We then tested the ability of stage  II cells from AKR/J donors to transplant 
into  irradiated  AKR/Cu  recipient  mice.  Data  of  Table  IV  shows  that  the 
transplantation  resistance  of AKR/Cu  recipients  was abrogated  by a  sublethal 
dose of irradiation administered  1 h before injection. Leukemias that developed 
in  irradiated  AKR/Cu  recipients  were  of donor  Thy-1  type  and  had a  mean 
latent period of 44 d, comparable to that observed in AKR/J recipients injected 
with the same cells. In contrast, leukemias that developed in unirradiated AKR/ 
Cu recipients were of recipient Thy-1  type and had a mean latent period of 99 
d. 
Differences in transplantation between AKR/J and AKR/Cu mice indicate that 
stage II cells display transformed properties that can be distinguished from stage 
III  or  primary  leukemia  cells,  indicative,  perhaps,  of progressive  changes  in 
transformed phenotype during development of frank disease.  The data suggest 
further that the transplantation resistance of stage II cells may involve an immune 
response to Thy-1  or Thy-l-associated antigens on the cell surface (42, 43). 
Discussion 
In  these  studies,  development  of leukemia  in  young  AKR/J  mice  injected 
intrathymically  with  a  cloned  isolate  of MCF  virus was relatively  synchronous 
with a  latent period  of frank disease  ranging  from  60  to  100  d  postinjection. O'DONNELL, WOLLER, AND CHU  929 
During this time interval (40-140 d of age), there were no age-dependent changes 
in thymus of control mice observable by flow cytometric analysis of T lymphocyte 
markers on thymocyte subpopulations or by histoiogic examination (unpublished 
data). 
Three stages of leukemogenesis were defined on the basis of flow cytometric 
analysis and transplantation bioassay of infected thymocytes during the preleu- 
kemic period before development of frank leukemia. By examining a population 
of  137  virus-injected mice,  we  were  able  to  show  that  each  stage  occurred 
sequentially at ~ 10-d intervals from 40 d postinjection onward. 
Stage I  was characterized by steady-state infection of the major thymocyte 
subpopulation by MCF virus as described previously (13,  14). A careful analysis 
of MCF virus infection in the minority lymphoblast populations has not been 
carried out and will require fractionation procedures to enrich for these cells. 
However, studies of RadLV infection in thymus of C57BL/Ka  mice (44,  45) 
indicated that lymphoblast cells were the first site of virus infection in that system. 
Infection then spreads throughout the thymus and in MCF 69Ll-injected AKR/ 
J  mice was complete by ~28 d  postinjection. Stage I  persisted maximally until 
~40 d  postinjection. During this time, no changes were observed in expression 
of alloantigens Thy-1,  Lyt-1,  Lyt-2,  L3T4a,  B2A2,  or  H-2K  on  the  major 
thymocyte subpopulations compared  with  controls.  The  expression  of PNA 
receptors on thymocytes also was identical to controls. Expression of MCF virus 
appeared to be confined predominantly to the small, cortisone-sensitive thymo- 
cyte population that  comprised 80%  of total  thymocytes, confirming Cloyd's 
recent studies (15). Thus, MCF virus expression was highest in the population of 
cells that appears to be destined for intrathymic cell death (18, 46). 
Stage II  was characterized by the emergence of a  novel population of cells 
with a modal light scatter of 30 that could be resolved from normal thymocyte 
subpopulations by fluorescent staining with monoclonal antibodies against H-2K 
and gp70 and, in particular, by a  monoclonal antibody B2A2 that is relatively 
specific for the population of small cortical thymocytes (22).  The relative pro- 
portion of stage II cells varied from  10  to  15%,  in AKR/J mice with thymus 
weight comparable to controls, to 45% in mice with obvious thymus enlargement 
(up to twice normal weight). Although stage II cells were not fractionated from 
the bulk thymocyte population, transplantation bioassays in AKR/J  mice indi- 
cated the presence of cells with transformed phenotype. However, cells at this 
stage did not transplant to AKR/Cu mice, unlike cells at stage III or primary 
leukemia cells, possibly an important marker of stage II cells.  Conversely, stage 
II cells from MCF 69Ll-injected AKR/Cu mice transplanted to AKR/Cu mice 
but not to AKR/J mice. These findings suggest a possible role of Thy-I in the 
transplantation  resistance  to  stage  II  cells  (42,  43).  The  involvement of an 
immune response  in  such  resistance  was  indicated  by  the  finding  that  the 
transplantation resistance could be abrogated by a sublethal dose of x irradiation. 
Recently (47), we assessed the clonality of cells at stage II of leukemogenesis 
compared with stage I by Southern blotting using an ecotropic MuLV-specific 
pl5(E)  probe  pAkv5,  which  recognizes all  pathogenic  MCF  viruses  but  not 
endogenous xenotropic sequences (47). No newly integrated proviruses in excess 
of germline ecotropic proviruses were observed in stage I thymocytes, consistent 930  STAGES IN  DEVELOPMENT OF  LEUKEMIA IN  AKR  MICE 
with the random integration in that population of infected cells. However, newly 
integrated  proviruses  with  stoichiometry  less  than  germline  proviruses  were 
observed in  all  stage  II  DNAs analyzed,  consistent  with  clonal expansion  of a 
subpopulation of cells (E. Fleissner and P. O'Donneil, unpublished data). 
Stage  III  appears  to  represent  clonal  outgrowth  of transformed  cells  with 
concomitant  disruption  of thymocyte homeostasis since the  normal  thymocyte 
subpopulations were no longer evident.  There  is considerable thymus enlarge- 
ment  at  this  stage  but  no  overt  signs  of  leukemia.  Analysis  of  27  primary 
leukemias  revealed  heterogeneity  in  cell  size  and  quantitative  expression  of 
alloantigens  that  was  not  observed at  earlier  stages.  The  phenotype  of each 
leukemia determined by dual parameter analysis appeared to be almost unique. 
Qualitatively, leukemia cells expressed all of the major thymocyte markers, Thy- 
1,  Lyt-1,  Lyt-2,  H-2K,  as  well  as  the  recently  described  markers  L3T4a  and 
B2A2.  Using  logarithmic  amplification,  no  significant  expression  of Ia  or TL 
antigens was detected above fluorescence of normal serum controls. All leukemias 
bound  fluoresceinated  PNA  as  did  the  novel  population  of stage  II  cells and 
stage III cells. These data,  therefore,  differ from previous reports of the phe- 
notype of AKR spontaneous  leukemias (16,  17,  21,  40).  In attempting  to use 
these  thymocyte  markers  to  identify  the  target  cell  for  transformation,  the 
phenotype of leukemia cells most closely resembles that of the small, cortisone- 
sensitive  thymocytes (18),  the  predominant  population  in  the  thymus  that  is 
nonfunctional  and  is  rapidly  turned  over  in  situ  (46).  Since  this  cell  type  is 
terminally  differentiated  and  noncycling  (18  and  unpublished  data),  a  likely 
candidate  for transformation  might  be its immediate  precursor,  a  lymphoblast 
subpopulation. 
We  were  struck  by  the  observation  that  the  majority  of virus-accelerated 
leukemias contained at  least two populations of cells that  could be resolved in 
dual parameter analysis using different markers,  most commonly Lyt-2. These 
distinct  cell  populations  were present  in  varying relative amounts  in  different 
leukemias and persisted upon transplantation.  It is unclear at present  whether 
multiple populations of leukemia cells in a single tumor represent the outgrowth 
of distinct  clones  or  if they are  related  in  some  way.  It  will  be  necessary  to 
separate these populations for analysis by Southern  blotting and further  trans- 
plantation studies to answer this question. 
Our study indicates  that  the rate  limiting  step in  MCF virus-induced  leuke- 
mogenesis is the establishment of steady-state infection in the thymus, an event 
that  took 30-40  d  at the dose of virus administered.  Cells with a  transformed 
phenotype were then observed as early as 42 d  postinjection by the techniques 
used.  This  represents  a  much  shorter  latent  period  for  transformation  by a 
nondefective leukemia virus than is generally assumed. Required, virus-induced 
events of transformation  may occur at low frequency, for example, by activating 
an oncogene (48), but could occur relatively early in the latent period as soon as 
a sufficiently large pool of infected cells is achieved. The remainder of the latent 
period until  development of frank disease might  require additional  mutational 
events  at  the  cellular  level,  such  as  trisomy  15  (49),  to  achieve  a  state  of 
autonomous  growth.  The  data  we  have  presented  are  consistent  with  such  a 
notion of tumor progression in leukemogenesis. Stage II cells appear to represent O'DONNELL, WOLLER, AND  CHU  931 
a  clonal, proliferating cell population with light scatter and antigen phenotype 
distinct from normal thymocyte subpopulations and from transformed cells at 
later stages. Transplantation properties of these cells in AKR/Cu vs. AKR/J mice 
suggest that stage II cells may not yet express a fully transformed phenotype. At 
stage III there are further cellular changes, detectable by flow cytometry, and a 
fully transformed  phenotype.  Finally,  primary  leukemia cells  show  additional 
variation in cellular phenotype as evidenced by the relative uniqueness of antigen 
expression quantitatively and the appearance of multiple populations of leukemic 
blasts.  There is also evidence to indicate that the phenotype of primary AKR 
leukemia cells does not remain static. Primary leukemia cells may undergo further 
selection  upon  serial  transplantation  in  vivo  or  in  tissue  culture,  leading  to 
increased tumorigenicity (E. Stockert, personal communication) or the capacity 
for autonomous growth in the absence of feeder cells in vitro (14, 50). Thus, the 
tumor phenotype of leukemia cells is likely to be a  composite of independent 
changes at the cellular level that must be analyzed separately at different stages 
for virus transformation to be understood. 
Summary 
Flow cytometric techniques involving correlated  dual parameter  analysis of 
fluorescence and light scatter and transplantation bioassays were used to describe 
a series of cellular changes in thymus of young (1-4 mo old) AKR mice during 
development  of mink  cell  focus-inducing (MCF)  virus-accelerated  leukemia. 
Three  stages  of  leukemogenesis  were  defined  before  appearance  of frankly 
leukemic mice. Stage I, apparent 28-40  d  after injection of MCF 69L1  virus, 
represented steady-state infection of thymocytes by MCF virus without apparent 
change in  light scatter  properties of the cells or in expression of alloantigens 
Thy-1, Lyt-1, Lyt-2, L3T4a, B2A2, or H-2K on the major thymocyte subpopu- 
lations. Expression of MCF virus was highest in the population of small cortical 
thymocytes. Stage II was observed at highest frequency 50-60  d  postinjection 
and represented the emergence of a clonal population of cells with transformed 
properties which could be resolved from normal thymocytes by light scatter and 
expression of B2A2, H-2K, and gp70 antigens. Stage III was observed at highest 
frequency at 70 d postinjection, when considerable enlargement of thymus had 
occurred,  and appeared to represent the outgrowth of fully transformed cells 
that replaced the normal thymocyte subpopulations. The alloantigen phenotype 
of blast cells from frankly leukemic mice did not differ qualitatively from that of 
stage II or stage III cells but displayed considerable heterogeneity with respect 
to quantitative expression of alloantigens and gp70. At least two populations of 
leukemic blasts could be resolved in the majority of primary thymomas analyzed. 
It is unclear whether these populations represent the outgrowth of independent 
clones of transformed  cells or  if they are  related  in  some way.  Our  data are 
consistent with MCF virus-induced transformation of cells in the lineage to small 
peanut agglutinin-positive, cortisone-sensitive thymocytes, a subpopulation that 
predominates in the thymus and which is thought to be destined for cell death 
in situ. 
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